Philip John Walther

1. DEVELOPMENTAL THERAPEUTICS OF SYSTEMIC UROLOGIC CANCER
A continuation of an ongoing effort in preclinical screening for effective new agents for the treatment of urologic malignancy-especially bladder and prostate - particular addressing issues of drug synergy.

2. p53 MUTATIONS IN PROSTATE CANCER
The presence of p53 mutations in malignancy has been considered an important genetic change in the multistep process of carcinogenesis-including radiation failure.

3. ASSOCIATION OF ONCOGENIC TYPES OF HUMAN PAPILLOMAVIRUS WITH UROLOGIC MALIGNANCY
Oncogenic types of HPV may be an important promoter-initiator of carcinogenesis in a variety of epithelia. Using polymerase chain reaction, we have analyzed clinical specimens of urologic malignancy.

4. TREATMENT OF RENAL CANCER WITH GAMMA-INTERFERON
Principal Investigator (Duke site) for multi-institutional Phase II-III trial to determine the efficacy of this biologic response modifier.

5. ANDROGEN RECEPTOR-MEDIATED TRANSCRIPTIONAL REGULATION IN ANDROGEN-DEPENDENT HUMAN PROSTATE CANCER XENOGRAFT